Current standard of care for septic shock
- PMID: 41359028
- DOI: 10.1007/s00134-025-08211-6
Current standard of care for septic shock
Erratum in
-
Author Correction: Current standard of care for septic shock.Intensive Care Med. 2025 Dec 18. doi: 10.1007/s00134-025-08262-9. Online ahead of print. Intensive Care Med. 2025. PMID: 41410710 No abstract available.
Abstract
Sepsis is a syndrome of life-threatening organ dysfunction that results from dysregulated host response to infection, with septic shock defined as persistent hypotension despite fluid resuscitation, a serum lactate > 2 mmol/L and the need for a vasopressor infusion to maintain a mean arterial pressure of at least 65 mmHg. Approximately, 49 million cases of sepsis are recorded worldwide annually, with 11 million sepsis-related deaths, the majority occurring in patients with septic shock. A substantial proportion of survivors suffer from moderate to severe functional limitations including physical, cognitive and psychological disability, exacerbation of pre-existing chronic conditions and a high incidence of re-hospitalisation in the first 12 months after the initial diagnosis. Optimal management of patients with septic shock requires prompt and reliable recognition of patients with sepsis who require additional haemodynamic support. Initially, patients will need judicious intravenous fluids and consideration of the need for vasopressors such as norepinephrine. Administration of appropriate antibiotics and consideration for control of the source of infection are also required. In the optimisation phase, depending on patients' comorbidities and response to therapy, the balance of fluid therapy, vasopressors and potentially the addition of an inotropic agent will need to be adjusted, based on clinical findings and haemodynamic and biochemical parameters. For those patients who do not respond to initial therapy, more intensive monitoring may be required with consideration of adjunctive therapies such as corticosteroids, vasopressin, angiotensin II or other rescue therapies to achieve cardiovascular stability. Once stability has been achieved, clinicians need to consider strategies to ameliorate the potential long-term effects on survivors, while keeping in mind the perspective and experience of their patients.
Keywords: Antibiotics; Antimicrobials; Critical care; Intensive care medicine; Resuscitation; Sepsis; Septic shock.
© 2025. Crown.
Conflict of interest statement
Declarations. Conflicts of interest: MSC is a Section Editor for Intensive Care Medicine. She has not taken part in the review or selection process of this article. AD: grants from the Australian National Health and Medical Research Council and Medical Research Future Fund paid to his Institution. MBS: MBS: Pfizer, AOP, Viatris, Biomerieux, Menarini. MSC: Edwards Lifesciences, Philips Healthcare, AOP, Laboratorie Agguetant, ESICM Chair Cardiodynamics section, ESICM Consensus on Shock and Haemodynamic Monitoring (co-chair), ESICM Consensus on Sepsis Induced Myocardial Dysfunction (co-chair). J.D.W. is supported by a Sr Clinical Research Grant from the Research Foundation Flanders (FWO, Ref. 1881020N) and consulted for Biomerieux, Menarini, MSD, Pfizer, Roche Diagnostics, ThermoFisher and Viatris (honoraria were paid to his institution). NH: Supported by a NHMRC Leadership Fellowship and Institutional Research Support from Baxter. MH is supported by a Tier 1 Canada Research Chair in Critical Illness Outcomes and the Recovery Continuum and receives funding support from the Canadian Institutes of Health. AKK: Medtronic, Edwards Lifesciences, Philips Research North America, Bayer Corporation, AOP, GE Healthcare, Innoviva Therapeutics, Viatris, SERB pharmaceuticals, Pharmazz Inc., Surviving Sepsis Campaign (Research Committee member), SCCM ESICM consensus definition of refractory septic shock (co-chair). Ongoing support Wake Forest CTSI: RAAS dysfunction in septic shock and NIH/NHLBI R01HL177834-01: Dysfunctional Renin Angiotensin System in Septic Shock. FRM: Member of The SSC 2026 guidelines, speaker’s fee from Baxter in 2025. AMD: Grants from Fischer Paykel and Terumo, and personal fees from Air Liquide, Terumo and Addmedica, all outside the submitted work. XM is a consultant for BD, Getinge and Pulsion Medical Systems. XM received honoraria for giving lectures from AOP health, Baxter healthcare, BD, Edwards Lifesciences, Getinge, Masimo and Philips healthcare. XM received an unrestricted research grant from Retia Medical, Masimo and Edwards Lifesciences. XM is an associate editor of Annals of Intensive Care, a member of the editorial board of Critical Care, and the editor-in-chief of Hemodynamics. SNM—Member of the Surviving Sepsis Campaign (SSC) 2026 Guidelines Committee and SSC Research Committee. Member of the Asia Pacific Sepsis Alliance (APSA). OH: AOP Healthcare and Viatris. DDB: Edwards Lifesciences, AOP Pharma, Pharmaz, Viatris. BV: Supported by a NHMRC Leadership Fellowship and Institutional Research Support from Baxter. JD, GH, JL declare no potential conflicts of interest.
References
-
- Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC (2016) The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315:801–810 - PubMed - PMC - DOI
-
- Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS, Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL, Naghavi M (2020) Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the global burden of disease study. Lancet 395:200–211 - PubMed - PMC - DOI
Publication types
LinkOut - more resources
Full Text Sources
